The Latest Breaking News from IDEXX Laboratories

IDEXX Laboratories has continued to underperform the S&P 500 over the past year, yet analysts remain moderately bullish on the stock’s prospects.

5 analysts have shared their evaluations of IDEXX Laboratories (NASDAQ:IDXX) during the recent three months, expressing a mix of bullish and bearish perspectives.

IDEXX Laboratories is scheduled to release its fiscal third-quarter earnings this month, and analysts project a single-digit profit growth.

IDEXX Laboratories underperformed the broader healthcare sector, but Wall Street analysts remain moderately optimistic about the stock’s prospects.

IDEXX Laboratories has underperformed the broader market over the past year, yet analysts remain moderately bullish on the stock’s prospects.

The healthcare industry's growth is driven by expanding healthcare needs, fast-rising demand for care services, and the increasing demand for smart medical devices. Given this backdrop, investors could consider buying fundamentally strong healthcare stocks such as IDEXX Laboratories (IDXX), Veeva Systems (VEEV), and Chemed Corporation (CHE) given their solid profitability…

IDXX Laboratories has recently underperformed the Healthcare sector, but Wall Street analysts are moderately optimistic about the stock’s prospects.

With an aging population worldwide, the rising prevalence of chronic diseases, and numerous technological advancements, the medical device sector stands primed for considerable growth and expansion. The industry tailwinds should benefit medical device stocks T2 Biosystems (TTOO) and IDEXX Laboratories (IDXX). However, which stock is poised for better gains this…

Upgrades

Upgrades

IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 15 years by 3.0% on an annualized basis producing an average annual return of 9.28%. Currently, IDEXX Laboratories has a market capitalization of $30.26 billion.